ID   B104 [Human lymphoma]
AC   CVCL_M498
DR   JCRB; JCRB0117
DR   JCRB; NIHS0144
DR   Wikidata; Q54752277
RX   PubMed=1729359;
RX   PubMed=1988498;
CC   Population: Japanese.
CC   Discontinued: JCRB; NIHS0144; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): JCRB=JCRB0117
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 10,11
ST   D16S539: 9,11
ST   D5S818: 11
ST   D7S820: 12
ST   TH01: 7,8
ST   TPOX: 8,11
ST   vWA: 16
DI   NCIt; C27907; B-cell neoplasm
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Children
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 02-05-24; Version: 10
//
RX   PubMed=1729359; DOI=10.4049/jimmunol.148.2.360;
RA   Ishigami T., Kim K.-M., Horiguchi Y., Higaki Y., Hata D., Heike T.,
RA   Katamura K., Mayumi M., Mikawa H.;
RT   "Anti-IgM antibody-induced cell death in a human B lymphoma cell line,
RT   B104, represents a novel programmed cell death.";
RL   J. Immunol. 148:360-368(1992).
//
RX   PubMed=1988498; DOI=10.4049/jimmunol.146.3.819;
RA   Kim K.-M., Yoshimura T., Watanabe H., Ishigami T., Nambu M., Hata D.,
RA   Higaki Y., Sasaki M.S., Tsutsui T., Mayumi M., Mikawa H.;
RT   "Growth regulation of a human mature B cell line, B104, by anti-IgM
RT   and anti-IgD antibodies.";
RL   J. Immunol. 146:819-825(1991).
//